Using Metabolic Endotoxemia as a measure of intestinal permeability and chronic immune activation, the University of North Texas conducted a double-blind placebo human clinical trial on the ability of bacillus spore bacteria to modulate how the gut and microbiome respond to a challenge meal. The findings were astounding.
Metabolic Endotoxemia (clinical leaky gut) is becoming recognized as a primary insult and driver of obesity, type 2 diabetes, heart disease, inflammatory bowel disease, cognitive decline, immune dysfunctions and even conditions like Parkinson’s disease. It is characterized by dramatically elevated serum LPS (endotoxin) levels after a meal, along with elevated triglycerides, poor insulin response and elevated inflammatory cytokines. Elevations in these markers are shown to be hallmarks of chronic disease and the number one cause of morbidity and mortality in the Western world.
This webinar will discuss the dramatic findings of the study and the reduction of these markers with commensal spore based probiotics. This is a first of its kind of study in the probiotic category.